CYTR on NASDAQ

CytRx

Biopharmaceutical research company in Los Angeles, California, USA

CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PALISADE BIO, INC., Artiva Biotherapeutics, Inc. or Inhibikase Therapeutics, Inc., or pick any stock.

TickerCYTR on NASDAQ¹
Industrypharmaceutical industry¹
HeadquartersLos Angeles¹
Websitewww.cytrx.com
Legal formDelaware corporation¹
Incorporated inDE⁵
Business address11726 San Vicente Boulevard, Suite 650, Los Angeles, Ca 90049⁵
Filer categoryNon-accelerated filer, Smaller reporting company⁵
LEI549300XDBGI8PTJRSA42⁴
StatusActive⁴
LEI statusLapsed (not renewed)⁴
Registered addressC/O The Prentice-Hall Corporation System, Inc., 19808 Wilmington, United States⁴

See how the biggest companies compare on our leaderboards

CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

-3299.2%Operating margin⁶

-5085.4%Net margin⁶

-62.4%Return on equity⁷

-$10.9MFree cash flow⁶

Where the money goes

Where each dollar of revenue went, fiscal 2018

Research and developmentInterest

Research and development18¢$388.8K
Interest81¢$1.7M
Income tax0¢$800

Out of $250.0K in revenue.⁶ The company lost money this year.

Financial statements

Fiscal year	2018
Revenue	$250.0K⁶
Research and development	$388.8K⁶
Operating expenses
Operating income	-$8.2M⁶
Interest	$1.7M⁶
Income before tax
Income tax	-$800⁶
Net income	-$12.7M⁶
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Fiscal year	2018
Cash	$21.4M⁶
Current assets	$22.5M⁶
Property, plant and equipment
Total assets	$22.9M⁶
Accounts payable
Current liabilities	$2.6M⁶
Long-term debt
Total liabilities
Retained earnings
Shareholders’ equity	$20.4M⁷
Shares outstanding	33.6M shares⁶

Fiscal year	2018
Cash from operations	-$10.9M⁶
Depreciation and amortization
Stock-based compensation
Capital spending	$11.5K⁶
Free cash flow	-$10.9M
Cash from investing
Dividends paid
Share buybacks
Cash from financing

Compare CytRx with another company

Leadership

Who has led CytRx, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Steven A. Kriegsman2014–2015

President

Steven A. Kriegsman2014

Chief financial officer

Chief operating officer

Eric Curtis2018

2010201520202025

Chief executive officerStephen Snowdy Jan 12, 2022 to Jan 29, 2024¹¹
Chief executive officerSteven A. Kriegsman Jun 21, 2006 to Aug 13, 2020¹²
ChairSteven A. Kriegsman Dec 16, 2014 to Dec 17, 2015¹³
PresidentSteven A. Kriegsman Dec 16, 2014 to Dec 16, 2014¹³
Chief financial officerJohn Y. Caloz Jan 6, 2009 to Jan 29, 2024¹⁴
Chief financial officerMitchell K. Fogelman Sep 14, 2007 to Nov 24, 2008¹⁵
Chief financial officerMatt Natalizio Jun 21, 2006 to Jun 21, 2006¹⁶
Chief operating officerEric Curtis May 21, 2018 to May 21, 2018¹⁷

Board members and other officers (23)

Vice President Drug DiscoveryFelix Kratz Jan 2, 2018 to Jan 2, 2018¹⁸
Senior VP-Drug DevelopmentShanta M.d. Chawla Jun 20, 2017 to Jun 20, 2017¹⁹
Chief Commercial OfficerOlivia C. Ware Jan 14, 2016 to Jan 14, 2016²⁰
Chief Medical OfficerDaniel J. Levitt Oct 14, 2009 to Dec 19, 2016²¹
Sr. V.P. of ManufacturingDavid Scott Geyer Dec 2, 2009 to Dec 13, 2011²²
Sr. VP - Drug DevelopmentDouglas Scott Wieland Nov 24, 2008 to Dec 19, 2016²³
Vice PresidentMark Tepper May 1, 2007 to May 10, 2007²⁴
Sr. VP Research & DevelopmentShi Chung Ng May 2, 2007 to Nov 24, 2008²⁵
Chief Accounting OfficerJohn Y. Caloz Nov 8, 2007 to Dec 14, 2009²⁶
Sr. VP - Drug DevelopmentJack R. Barber Jun 21, 2006 to Jul 6, 2009²⁷
Board memberCary J. Claiborne Jul 28, 2022 to Jan 29, 2024²⁸
Board memberJennifer K. Simpson Aug 11, 2021 to Jan 29, 2024²⁹
Board memberJoel K. Caldwell Sep 6, 2017 to Jan 29, 2024³⁰
Board memberEarl W. Brien Dec 6, 2016 to Aug 20, 2020³¹
Board memberAnita J. Chawla Mar 11, 2015 to Dec 19, 2016³²
Board memberEric Jay Selter May 4, 2015 to Dec 17, 2015³³
Board memberCheryl Cohen Jun 25, 2015 to Dec 17, 2015³⁴
Board memberSteven A. Kriegsman Jun 21, 2006 to Aug 13, 2020¹²
Board memberJoseph Rubinfeld Jul 19, 2006 to Dec 19, 2016³⁵
Board memberLouis Ignarro Jul 19, 2006 to Aug 13, 2020³⁶
Board memberMarvin R. Selter Jul 19, 2006 to Dec 12, 2013³⁷
Board memberMax Link Jul 19, 2006 to Dec 12, 2013³⁸
Board memberRichard J. Wennekamp Jul 19, 2006 to Dec 16, 2014³⁹

Former names

CYTRX CORPNov 7, 1995 to Sep 23, 2022⁵

Timeline

Jan 12, 2022New chief executive Stephen Snowdy becomes CEO¹¹
Jun 21, 2006New chief executive Steven A. Kriegsman becomes CEO¹²
Jan 2, 1990Went public Listed on NASDAQ¹

Filings

71 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 22 major events, 10 insider forms, 3 large holders, 1 private raises, 20 other. The latest 20:

Jul 31, 20258-K EDGAR
Jun 27, 20258-K EDGAR
May 14, 202510-Q EDGAR
Apr 16, 20258-K EDGAR
Mar 28, 202510-K EDGAR
Feb 21, 2025SEC STAFF ACTION EDGAR
Nov 14, 202410-Q EDGAR
Oct 9, 20248-K EDGAR
Aug 20, 2024DEFA14A EDGAR
Aug 20, 2024DEF 14A EDGAR
Aug 14, 202410-Q EDGAR
Jun 6, 20248-K EDGAR
May 15, 202410-Q EDGAR
Mar 27, 202410-K EDGAR
Feb 14, 2024SC 13G/A EDGAR
Jan 29, 20244 EDGAR
Jan 29, 20244 EDGAR
Jan 29, 20244 EDGAR
Jan 29, 20244 EDGAR
Jan 29, 20244 EDGAR

The 71 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

ARMISTICE CAPITAL, LLCSC 13G/A, 3 filings Feb 15, 2022 to Feb 14, 2024⁴⁰

Money raised

Private offerings the company reported to the SEC on Form D.

Jul 13, 2021Raised $8.2 million in a private offering of equity Form D: $18.2 million offered in all Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataCytRx on Wikidata
2
SEC EDGARCytRx filings on SEC EDGAR
3
WikipediaCytRx on Wikipedia
4
GLEIFCytRx LEI record (549300XDBGI8PTJRSA42)
5
SEC EDGARCytRx filings on SEC EDGAR
6
SEC EDGARCytRx 10-K for fiscal 2018
7
SEC EDGARCytRx 10-K for fiscal 2018
8
SEC EDGARCytRx 10-Q for fiscal 2024
9
SEC EDGARCytRx 10-Q for fiscal 2024
10
SEC EDGARCytRx 10-Q for fiscal 2025
11
SEC EDGARStephen Snowdy, Chief executive officer
12
SEC EDGARSteven A. Kriegsman, Chief executive officer
13
SEC EDGARSteven A. Kriegsman, Chair
14
SEC EDGARJohn Y. Caloz, Chief financial officer
15
SEC EDGARMitchell K. Fogelman, Chief financial officer
16
SEC EDGARMatt Natalizio, Chief financial officer
17
SEC EDGAREric Curtis, Chief operating officer
18
SEC EDGARFelix Kratz, Vice President Drug Discovery
19
SEC EDGARShanta M.d. Chawla, Senior VP-Drug Development
20
SEC EDGAROlivia C. Ware, Chief Commercial Officer
21
SEC EDGARDaniel J. Levitt, Chief Medical Officer
22
SEC EDGARDavid Scott Geyer, Sr. V.P. of Manufacturing
23
SEC EDGARDouglas Scott Wieland, Sr. VP - Drug Development
24
SEC EDGARMark Tepper, Vice President
25
SEC EDGARShi Chung Ng, Sr. VP Research & Development
26
SEC EDGARJohn Y. Caloz, Chief Accounting Officer
27
SEC EDGARJack R. Barber, Sr. VP - Drug Development
28
SEC EDGARCary J. Claiborne, Board member
29
SEC EDGARJennifer K. Simpson, Board member
30
SEC EDGARJoel K. Caldwell, Board member
31
SEC EDGAREarl W. Brien, Board member
32
SEC EDGARAnita J. Chawla, Board member
33
SEC EDGAREric Jay Selter, Board member
34
SEC EDGARCheryl Cohen, Board member
35
SEC EDGARJoseph Rubinfeld, Board member
36
SEC EDGARLouis Ignarro, Board member
37
SEC EDGARMarvin R. Selter, Board member
38
SEC EDGARMax Link, Board member
39
SEC EDGARRichard J. Wennekamp, Board member
40
SEC EDGARARMISTICE CAPITAL, LLC SC 13G/A on CytRx